Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without human clinical trial data
PubMed 33828455 · doi:10.3389/fnins.2021.650971
What was done
This narrative review summarizes neurobiological mechanisms through which vagus nerve signaling regulates intestinal inflammation. It details the anatomical composition of the vagus nerve (80% afferent, 20% efferent) and outlines the neuroimmune pathways linking bioelectronic stimulation to cytokine modulation in inflammatory bowel disease.
What was found
The abstract reports no empirical clinical data, sample sizes, or quantitative therapeutic outcomes. It describes mechanistic pathways wherein efferent vagal acetylcholine release inhibits macrophage tumor necrosis factor (TNF) alpha production via enteric nervous system interneurons and splenic sympathetic innervation. It also details afferent activation of the hypothalamic-pituitary-adrenal axis and central spinal sympathetic reflexes.
Why it matters
Bioelectronic vagus nerve stimulation represents a potential non-pharmacologic alternative or adjunct to conventional anti-TNF-alpha medications for Crohn's disease and ulcerative colitis.
Limits
The abstract is purely mechanistic and narrative, containing no patient data, randomized comparisons, quantitative effect sizes, stimulation parameters, or safety and tolerability endpoints.
Cited by
- supports Approximately 80% of vagus nerve fibers are afferent (transmitting signals from gut to brain), while only 20% are efferent (transmitting from brain to gut).